Hundreds of biotech investors are gearing up for one of the hottest events in the calendar - the BIO CEO & Investor conference in New York.
Now in its 20th year, it offers investors the chance to meet management from top public and private biotech firms, and for companies to present their stories.
It takes place from February 12 to 13 at the New York Marriott Marquis on Broadway. Get the details of the event HERE..
Companies to be featured include Savara Inc (NASDAQ: SVRA), which raised nearly US$100mln in 2017 and has many near-term milestones for 2018.
The group is focused on novel therapies for the treatment of rare respiratory diseases and its late-stage pipeline includes: Molgradex, which is in Phase 3 trials for aPAP and AeroVanc, a Phase 3 stage inhaled vancomycin for treatment of MRSA infection in Cystic Fibrosis.
Meanwhile, NewLink Genetics (NASDAQ: NLNK) is focused on a very topical area of medicine - immuno-oncology.
The group is working on product candidates, which target the IDO pathway. IDO regulates immune function through control of tryptophan levels.
The firm expects imminent initiation of a Phase 3 trial in melanoma and a Phase 2 data readout in 2018 and it has reported promising early data in both AML and pancreatic cancer.
It also has a collaboration with drugs major Astra Zeneca (LON:AZN) for a Phase 2 programme in pancreatic cancer.
Newron Pharmaceuticals (SWX: NWRN) is another company presenting at the conference.
It is advancing novel therapies for diseases of the central and peripheral nervous system. It has received approval for Xadago (safinamide) for Parkinson’s disease in the EU, Switzerland and the USA, and is commercialized by Newron’s Partner Zambon, in the US.
Newron is also developing has a pipeline of promising rare disease treatments including sarizotan for patients with Rett syndrome and ralfinamide for patients with specific rare pain indications. It also has Evenamide as the potential first add on therapy for the treatment of patients with positive symptoms of schizophrenia.
Elsewhere, Integrity Applications Inc. (OTCQB: IGAP) is focused on the design, development, and commercialization of non-invasive glucose monitoring technologies for people with type 2 diabetes and prediabetes.
Private firms Xontogeny and Landos Biopharma will also be at the New York event.
The former is an accelerator firm focused on development and investment innovations that are too large for Angel investors but too small for the traditional venture capital route.
The latter is focused on development of first-in-class oral therapeutics for patients with autoimmune diseases using a novel pathway.